DL-Mepivacaine en es it fr

DL-Mepivacaine Brand names, DL-Mepivacaine Analogs

DL-Mepivacaine Brand Names Mixture

  • No information avaliable

DL-Mepivacaine Chemical_Formula


DL-Mepivacaine RX_link


DL-Mepivacaine fda sheet

DL-Mepivacaine FDA

DL-Mepivacaine msds (material safety sheet)

DL-Mepivacaine MSDS

DL-Mepivacaine Synthesis Reference

No information avaliable

DL-Mepivacaine Molecular Weight

129.164 g/mol

DL-Mepivacaine Melting Point

223-226 oC

DL-Mepivacaine H2O Solubility

Freely soluble as HCl salt

DL-Mepivacaine State


DL-Mepivacaine LogP


DL-Mepivacaine Dosage Forms

Extended release tablet (500 mg or 1000 mg)

DL-Mepivacaine Indication

For use as an adjunct to diet and exercise to improve glycemic control in adult patients (18 years and older) with type 2 diabetes.

DL-Mepivacaine Pharmacology

Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease.

DL-Mepivacaine Absorption

Absorbed over 6 hours, bioavailability is 50 to 60% under fasting conditions. Food delays absorption.

DL-Mepivacaine side effects and Toxicity

Acute oral toxicity (LD50): 350 mg/kg [Rabbit]. It would be expected that adverse reactions of a more intense character including epigastric discomfort, nausea, and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise and headache might be seen.

DL-Mepivacaine Patient Information

DL-Mepivacaine Organisms Affected

Humans and other mammals